KR102377805B1 - 피리미딘 및 그의 변이체, 및 그의 용도 - Google Patents

피리미딘 및 그의 변이체, 및 그의 용도 Download PDF

Info

Publication number
KR102377805B1
KR102377805B1 KR1020187029805A KR20187029805A KR102377805B1 KR 102377805 B1 KR102377805 B1 KR 102377805B1 KR 1020187029805 A KR1020187029805 A KR 1020187029805A KR 20187029805 A KR20187029805 A KR 20187029805A KR 102377805 B1 KR102377805 B1 KR 102377805B1
Authority
KR
South Korea
Prior art keywords
compound
mmol
mixture
formula
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187029805A
Other languages
English (en)
Korean (ko)
Other versions
KR20180128015A (ko
Inventor
로널드 찰스 홀리
프라바 이브라힘
안토니 피. 포드
조엘 알. 게버
Original Assignee
애퍼런트 파마슈티컬스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애퍼런트 파마슈티컬스 인크. filed Critical 애퍼런트 파마슈티컬스 인크.
Publication of KR20180128015A publication Critical patent/KR20180128015A/ko
Application granted granted Critical
Publication of KR102377805B1 publication Critical patent/KR102377805B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020187029805A 2016-03-25 2017-03-20 피리미딘 및 그의 변이체, 및 그의 용도 Active KR102377805B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662313334P 2016-03-25 2016-03-25
US62/313,334 2016-03-25
PCT/US2017/023126 WO2017165255A1 (en) 2016-03-25 2017-03-20 Pyrimidines and variants thereof, and uses therefor

Publications (2)

Publication Number Publication Date
KR20180128015A KR20180128015A (ko) 2018-11-30
KR102377805B1 true KR102377805B1 (ko) 2022-03-22

Family

ID=59900805

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187029805A Active KR102377805B1 (ko) 2016-03-25 2017-03-20 피리미딘 및 그의 변이체, 및 그의 용도

Country Status (11)

Country Link
US (2) US10662162B2 (enExample)
EP (1) EP3433258B1 (enExample)
JP (1) JP6902045B2 (enExample)
KR (1) KR102377805B1 (enExample)
CN (1) CN108779119B (enExample)
AU (1) AU2017237929B2 (enExample)
CA (1) CA3018180C (enExample)
MA (1) MA44489A (enExample)
MX (1) MX384368B (enExample)
RU (1) RU2760733C2 (enExample)
WO (1) WO2017165255A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017233841B9 (en) 2016-03-14 2021-09-09 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
KR102377805B1 (ko) * 2016-03-25 2022-03-22 애퍼런트 파마슈티컬스 인크. 피리미딘 및 그의 변이체, 및 그의 용도
JP7063902B2 (ja) 2016-12-19 2022-05-09 ノバルティス アーゲー 新たなピコリン酸誘導体及び中間体としてのその使用
AU2017378785B2 (en) * 2016-12-20 2021-07-29 Afferent Pharmaceuticals, Inc. Crystalline salts and polymorphs of a P2X3 antagonist
CN111094266B (zh) * 2017-11-01 2023-09-29 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途
CN107778255B (zh) * 2017-11-16 2019-10-25 山东大学 一种二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用
CN114007619B (zh) * 2019-04-30 2024-08-06 北京泰德制药股份有限公司 二氨基嘧啶类化合物治疗咳嗽的方法
CN114007620B (zh) * 2019-04-30 2024-08-06 北京泰德制药股份有限公司 二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法
MX2021013300A (es) * 2019-04-30 2022-02-11 Beijing Tide Pharmaceutical Co Ltd Forma sólida de un compuesto de diaminopirimidina o un hidrato del mismo, método de preparación del mismo, y aplicación del mismo.
WO2020244607A1 (zh) * 2019-06-06 2020-12-10 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953567A (en) * 1956-11-23 1960-09-20 Burroughs Wellcome Co 5-phenylmercaptopyrimidines and method
CA2369945A1 (en) * 1999-04-06 2000-10-12 James L. Kelley Neurotrophic thio substituted pyrimidines
ATE354573T1 (de) * 2000-12-21 2007-03-15 Vertex Pharma ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß
BR122018003623B8 (pt) * 2004-03-05 2021-07-27 Hoffmann La Roche diaminopirimidinas, seus usos, e composição farmacêutica
JP4850911B2 (ja) * 2005-09-01 2012-01-11 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ３およびｐ２ｘ２／３モジュレーターとしてのジアミノピリミジン
WO2007025925A1 (en) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
ES2562056T3 (es) * 2005-09-01 2016-03-02 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores P2X3 y P2X2/3
CN101253159B (zh) * 2005-09-01 2011-12-07 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物
AU2007304280B2 (en) * 2006-10-04 2013-01-31 F. Hoffmann-La Roche Ag Process for synthesis of phenoxy diaminopyrimidine derivatives
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
WO2008104472A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag 2, 4 -diaminopyrimidine derivatives and their use as p2x antagonists or as prodrugs thereof
WO2009057827A1 (en) * 2007-10-31 2009-05-07 Nissan Chemical Industries, Ltd. Pyridazinone derivatives and use thereof as p2x7 receptor inhibitors
GB2471713A (en) 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
TWI637949B (zh) * 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
US9284279B2 (en) * 2013-08-23 2016-03-15 Afferent Pharmaceuticals, Inc. Substituted pyrimidines for treatment of acute cough, chronic cough and urge to cough
EP3164132A4 (en) * 2014-07-03 2018-02-21 Afferent Pharmaceuticals Inc. Methods and compositions for treating diseases and conditions
AU2017233841B9 (en) * 2016-03-14 2021-09-09 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
KR102377805B1 (ko) * 2016-03-25 2022-03-22 애퍼런트 파마슈티컬스 인크. 피리미딘 및 그의 변이체, 및 그의 용도

Also Published As

Publication number Publication date
CN108779119B (zh) 2022-02-08
KR20180128015A (ko) 2018-11-30
CA3018180C (en) 2024-02-20
MA44489A (fr) 2019-01-30
US10662162B2 (en) 2020-05-26
EP3433258A4 (en) 2019-10-30
AU2017237929A1 (en) 2018-09-13
WO2017165255A1 (en) 2017-09-28
MX2018011622A (es) 2019-03-28
US11230532B2 (en) 2022-01-25
BR112018069105A2 (pt) 2019-01-29
MX384368B (es) 2025-03-14
RU2760733C2 (ru) 2021-11-30
EP3433258A1 (en) 2019-01-30
US20190055202A1 (en) 2019-02-21
JP2019510025A (ja) 2019-04-11
RU2018137032A (ru) 2020-04-27
CA3018180A1 (en) 2017-09-28
US20200239421A1 (en) 2020-07-30
AU2017237929B2 (en) 2021-04-15
CN108779119A (zh) 2018-11-09
EP3433258B1 (en) 2023-07-19
JP6902045B2 (ja) 2021-07-14
RU2018137032A3 (enExample) 2020-05-22

Similar Documents

Publication Publication Date Title
KR102377805B1 (ko) 피리미딘 및 그의 변이체, 및 그의 용도
KR102489454B1 (ko) 피리미딘 및 그의 변이체, 및 그의 용도
JP7502337B2 (ja) Ｋｒａｓ ｇ１２ｃインヒビター及びその使用
EP2183224B1 (en) 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (s1p) receptor for the treatment of multiple sclerosis
CN104684899B (zh) 取代的磺酰胺化合物
RU2505534C2 (ru) Производные хиназолина, ингибирующие активность egfr
KR20150128722A (ko) 카텝신 c의 억제제로서 치환된 2-아자-바이사이클로[2.2.1]헵탄-3-카복실산(벤질-시아노-메틸)-아미드
WO2022170802A1 (zh) 一种作为sos1抑制剂的嘧啶并吡啶酮类衍生物、其制备方法及用途
CZ20033431A3 (en) 5-ht receptor ligands and uses thereof
WO2016169421A1 (zh) 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用
CN110461838A (zh) 噁二唑瞬时受体电位通道抑制剂
JP2025533108A (ja) Ｇｓｐｔ１分解剤、分解剤を含む組成物、及びそれを使用する方法
BR112018069105B1 (pt) Composto de pirimidina, composição e uso do mesmo
HK40048952A (en) Heterocyclic compound, intermediate, preparation method therefor and application thereof
HK40004688B (zh) 双环脯氨酸化合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181016

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200309

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210325

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20210914

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220310

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220318

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220318

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20241223

Start annual number: 4

End annual number: 4